High-Cost Medicines Through Private Pharmacies in Greece: What the New EOPYY Model Means for Manufacturers

Since 5 February 2026, patients in Greece receiving certain high-cost medicines have been able to collect them from a private community pharmacy of their choice, rather than only from EOPYY’s own pharmacies. The first phase covers medicines for cancer and multiple sclerosis. For patients, the change means less queuing and travel. For marketing authorisation holders, it changes the distribution chain, the volumes moving through it and the points where product quality and patient information must be controlled.

How the new model works

  • EOPYY approves the prescription, and the patient is notified electronically.
  • The patient chooses a participating private pharmacy, which must be registered and certified through EOPYY’s platform.
  • Certified distributors deliver the medicine to the pharmacy, maintaining the cold chain where required.
  • The pharmacist verifies the patient’s identity before dispensing and can refuse to dispense if there are irregularities.
  • Under a collective agreement between EOPYY and the Panhellenic Pharmaceutical Association, pharmacists receive a professional fee of €20 per prescription plus applicable taxes.

Reported figures at launch pointed to around 20,000 prescriptions a month through private pharmacies in the first phase, compared with around 1,500 a month under the previous arrangement, with a target of substantially higher volumes during 2026.

What changes for manufacturers

  • Distribution and GDP: high-value, often temperature-sensitive products now travel further down the chain, to many more delivery points. Quality agreements, transport validation and temperature-excursion handling with distributors need to reflect this.
  • Supply planning: demand patterns may shift as dispensing spreads geographically, and the existing Greek rules on supply and shortage notification still apply.
  • Falsified medicines safeguards: more dispensing points mean more verification and decommissioning events under the Falsified Medicines Directive.
  • Pharmacovigilance and patient information: community pharmacists become a more frequent point of contact for patients on specialist therapies, which can affect adverse event reporting routes and the reach of any additional risk minimisation materials.
  • Market access: easier access may support uptake, but high-cost medicines remain subject to EOPYY’s reimbursement controls, clawback and rebate mechanisms.

Questions to ask now

  • Do your distributor agreements cover delivery to community pharmacies for these products?
  • Are cold-chain controls validated for the last mile, including storage at the pharmacy?
  • Do community pharmacists have access to the educational materials your risk management plan requires?
  • Will future phases bring further therapeutic areas, and possibly your products, into scope?

How PQRA helps

PQRA supports marketing authorisation holders in Greece with GDP and distributor oversight, supply and shortage obligations, pharmacovigilance and risk minimisation, and reimbursement strategy with EOPYY.

Contact PQRA about high-cost medicine distribution in Greece

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *